The globe PEGylated Protein Therapeutics Market is poised to reach over $22.3 billion in value by 2028 and achieve over 6.4% CAGR over the 2022-2028 forecast period.

PEGylation is the process by which polyethylene glycol polymer chains are attached covalently and non-covalently to molecules such as a drug, therapeutic protein, or vesicle. The market for PEGylated protein therapeutics is expected to grow significantly during the forecast period, mainly driven by an increasing demand for PEGylation, an increase in the number of chronic diseases and the presence of powerful drugs in the pipeline. In addition, PEGylated molecules offer advantages such as extended half-life, reduced toxicity, lower immunogenicity, and increased proteolytic protection that support market growth. On the other hand, higher PEGylation process costs and certain drug patent expirations are expected to dampen market growth. The ongoing clinical trials undertaken by many pharmaceutical companies along with the high demand for disease-specific novel treatments are expected to accelerate the overall growth of the PEGylated protein therapeutics market over the forecast period. Additionally, an increase in special labeling by regulators is expected to fuel the overall growth of the market. However, the limited operating revenue opportunities of many pharmaceutical companies for the research and development of targeted therapies as well as low healthcare budgets in some developing countries are expected to slow the growth of the PEGylated protein therapeutics market in the coming years. With over 10 US FDA approved PEGylated drugs and 20 drugs in clinical trials, PEGylated protein therapeutics are expected to be an extremely lucrative market in terms of revenue. First generation PEGylated drugs were obtained by random PEGylation. Adagen and Oncaspar are two examples. The majority of drugs in clinical trials are PEGylated with larger PEGs than the first generation…